Roche News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

24.04.24	[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19 (Roche Holding AG)
19.04.24	FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer (Roche Holding AG)
17.04.24	Roche’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS (Roche Holding AG)
15.04.24	[Ad hoc announcement pursuant to Art. 53 LR] Roche’s Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study (Roche Holding AG)
11.04.24	Roche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimer's disease diagnosis (Roche Holding AG)
26.03.24	Roche receives FDA approval for the first molecular test to screen for malaria in blood donors (Roche Holding AG)
12.03.24	Roche Annual General Meeting 2024 (Roche Holding AG)
25.02.24	New England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions across multiple foods in people with food allergies (Roche Holding AG)
16.02.24	FDA approves Xolair as first and only medicine for children and adults with one or more food allergies (Roche Holding AG)
01.02.24	New long-term data for Roche’s Vabysmo show sustained retinal drying and vision improvements in retinal vein occlusion (RVO) (Roche Holding AG)
01.02.24	[Ad hoc announcement pursuant to Art. 53 LR] Roche exceeds guidance and achieves sales growth of 1% (CER) for 2023 despite sharp COVID-19 sales decline (Roche Holding AG)
16.01.24	European Commission approves Roche’s Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types (Roche Holding AG)
29.12.23	Roche enters into a definitive agreement to acquire LumiraDx's Point of Care technology combining multiple diagnostic modalities on a single platform (Roche Holding AG)
19.12.23	FDA grants priority review to Xolair (omalizumab) for children and adults with food allergies based on positive National Institutes of Health phase III study results (Roche Holding AG)
15.12.23	Roche named among top three most sustainable healthcare companies in the Dow Jones Sustainability Indices (Roche Holding AG)
11.12.23	New data for Roche’s Columvi and Lunsumio presented at ASH 2023 support continued benefit for people with lymphoma (Roche Holding AG)
09.12.23	New data reinforce the benefit of early preventative treatment with Roche’s Hemlibra for babies with severe haemophilia A (Roche Holding AG)
08.12.23	Roche’s inavolisib combination reduces the risk of disease progression by 57% in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation (Roche Holding AG)
11.04.23	Roche introduces navify® Algorithm Suite, a digital library of medical algorithms that enhances clinical decision-making to optimise patient care (PR Newswire)
05.12.22	Roche Announces Brad Moore as President and CEO of Roche Diagnostics North America (PR Newswire)
05.03.19	Roche Annual General Meeting 2019 (GlobeNewswire)
10.10.18	OCREVUS (Ocrelizumab) fünf-Jahresdaten zeigen, dass ein früher Therapiebeginn bei schubförmiger und primär progredienter multipler Sklerose das Fortschreiten der Erkrankung reduziert (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

20:03		Schwache Performance in New York: Dow Jones gibt nachmittags nach
18:01		Gewinne in New York: Dow Jones verbucht am Mittwochmittag Zuschläge
17:58		Börse Zürich in Grün: Anleger lassen SLI zum Ende des Mittwochshandels steigen
17:58		Börse London: FTSE 100 zum Ende des Mittwochshandels mit positivem Vorzeichen
17:58		Starker Wochentag in Europa: STOXX 50 klettert zum Handelsende
17:58		Mittwochshandel in Zürich: SMI letztendlich mit Gewinnen

20:03

Schwache Performance in New York: Dow Jones gibt nachmittags nach

18:01

Gewinne in New York: Dow Jones verbucht am Mittwochmittag Zuschläge

17:58

Börse Zürich in Grün: Anleger lassen SLI zum Ende des Mittwochshandels steigen

17:58

Börse London: FTSE 100 zum Ende des Mittwochshandels mit positivem Vorzeichen

17:58

Starker Wochentag in Europa: STOXX 50 klettert zum Handelsende

17:58

Mittwochshandel in Zürich: SMI letztendlich mit Gewinnen

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Givaudan	4’040.00	1.71 %	K V
Geberit	547.80	1.59 %	K V
Part Grp Hldg	1’297.00	1.49 %	K V
ABB	51.94	1.29 %	K V
Swiss Life Hldg	691.80	1.26 %	K V
Zurich Insur Gr	548.00	-0.18 %	K V
Kuehne+Nagel Int	210.90	-0.33 %	K V
Swiss Re	128.20	-0.66 %	K V
Sonova Hldg	293.00	-0.85 %	K V
Novartis	87.94	-0.92 %	K V

Nachrichten zu Roche AG (Genussschein)

Aktien Top/Flop

Roche Peer Group Nachrichten

Meistgelesene Nachrichten